The mean C max was 1.01 IU per milliliter (95% CI, 0.92 to 1.09) with recombinant ADAMTS13 and 0.19 IU per milliliter (95% CI, 0.15 to 0.22) with standard therapy (Table S8); in other words, on ...

Ji, M., et al. (2024) ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury. A Randomized Clinical Trial. Journal of Clinical and Translational Hepatology ...

OSAKA, Japan & CAMBRIDGE, Mass., August 07, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADZYNMA® (recombinant ADAMTS13) for the treatment of ...

Patients were included who had a recorded ADAMTS13 activity level below 10%. In total, the authors’ cohort consisted of 221 patients with severe ADAMTS13 deficiency.

Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2024; 390 (18): 1690 DOI: 10.1056/NEJMoa2402567 ...

DOI 10.14218/JCTH.2024.00233 Article Title ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury Article Publication Date 22-Dec-2024 ...

About Recombinant ADAMTS13 (rADAMTS13) rADAMTS13 is the first and only recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (ADAMTS13) enzyme replacement therapy ...

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic ...

Today, plasma is the primary source of exogenous ADAMTS13 for treatment and prophylaxis in patients with hereditary TTP. Acute episodes can be treated with plasma infusions, with therapeutic ...

OSAKA, Japan& CAMBRIDGE, Mass.---- Takeda today announced that the European Commission approved ADZYNMA ® for the treatment of ADAMTS13 deficiency in children and adult patients with congenital ...